Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Cetuximab (Primary) ; Encorafenib (Primary) ; Ulixertinib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions
Most Recent Events
- 26 Aug 2024 Planned primary completion date changed from 28 Mar 2026 to 28 Mar 2028.
- 21 Mar 2024 Status changed from suspended to recruiting.
- 29 Jan 2024 Status changed from not yet recruiting to suspended due to PI Request.